secukinumab

Secukinumab is a fully human IgG1κ monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of several autoimmune diseases. By inhibiting IL-17A, secukinumab reduces inflammation and helps control symptoms in conditions such as moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, juvenile psoriatic arthritis, and hidradenitis suppurativa. It is administered via subcutaneous injection or intravenous infusion. Secukinumab was developed by Novartis and is marketed under the brand name Cosentyx[1][2][4][5][6][7][8].

Brand names

Cosentyx

Other names

secukinumab biosimilar